D.A. Davidson & CO. Increases Stock Holdings in Kenvue Inc. (NYSE:KVUE)

D.A. Davidson & CO. raised its position in shares of Kenvue Inc. (NYSE:KVUE) by 305.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 157,247 shares of the company’s stock after buying an additional 118,510 shares during the quarter. D.A. Davidson & CO.’s holdings in Kenvue were worth $3,357,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Grove Bank & Trust lifted its position in Kenvue by 438.4% during the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock valued at $25,000 after buying an additional 947 shares during the period. Geneos Wealth Management Inc. purchased a new position in Kenvue during the fourth quarter valued at $29,000. Ashton Thomas Securities LLC purchased a new position in shares of Kenvue in the 3rd quarter worth about $35,000. Fortitude Family Office LLC raised its position in shares of Kenvue by 106.6% in the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock worth $32,000 after purchasing an additional 777 shares during the last quarter. Finally, Versant Capital Management Inc boosted its stake in Kenvue by 300.8% in the 4th quarter. Versant Capital Management Inc now owns 1,920 shares of the company’s stock worth $41,000 after purchasing an additional 1,441 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on KVUE. UBS Group dropped their price target on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating on the stock in a research note on Friday, February 7th. Piper Sandler upgraded shares of Kenvue from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $21.00 to $26.00 in a research note on Monday, January 6th. Barclays dropped their price target on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating on the stock in a research note on Friday, January 17th. Citigroup dropped their price target on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 15th. Finally, Deutsche Bank Aktiengesellschaft cut shares of Kenvue from a “buy” rating to a “hold” rating and dropped their price target for the stock from $25.00 to $24.00 in a research note on Thursday, December 12th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $23.00.

Kenvue Price Performance

NYSE KVUE opened at $22.38 on Friday. Kenvue Inc. has a 52 week low of $17.67 and a 52 week high of $24.46. The firm has a market capitalization of $42.90 billion, a P/E ratio of 42.22, a PEG ratio of 2.57 and a beta of 1.45. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The company has a 50-day moving average price of $21.29 and a 200-day moving average price of $22.14.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, meeting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Equities research analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th will be issued a $0.205 dividend. This represents a $0.82 annualized dividend and a yield of 3.66%. The ex-dividend date of this dividend is Wednesday, February 12th. Kenvue’s dividend payout ratio is 154.72%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.